MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Wednesday, April 25, 2012

Sanofi’s Lemtrada Improves Disability Scores in MS Patients

By Albertina Torsoli on April 24, 2012

Sanofi (SAN), France’s largest drugmaker, said its experimental medicine Lemtrada led to an improvement in disability scores in patients with multiple sclerosis compared to an older treatment.
Lemtrada, also known as alemtuzumab, slowed the progression of disability versus Merck KGaA (MRK)’s Rebif in a late-stage trial, and scores improved in some patients who were given Lemtrada in the two-year study, suggesting a reversal of disability, Paris- based Sanofi said today in an e-mailed statement.
At two years, 29 percent of patients treated with Lemtrada had experienced a six-month reduction in disability, compared with 13 percent of those treated with Rebif, said Sanofi, which presents full data from the trial at the 2012 American Academy of Neurology meeting in New Orleans today.
The disability data “is big news,” Michael Panzara, Genzyme’s therapeutic area head for multiple sclerosis, immune diseases and neurology, said in a telephone interview today. “Alemtuzumab versus Rebif improves function; that’s unique.”

Comments are appreciated. Note that All comments are moderated 
 If not yet receiving our weekly e-Newsletter Click here to: REGISTER -
so that you can be kept up to date with MS News and Information
LIKE this BLOG? - Please click the LIKE button top left


No comments: